Literature DB >> 10424424

Construction of a recombinant live oral vaccine from a non-toxigenic strain of Vibrio cholerae O1 serotype inaba biotype E1 Tor and assessment of its reactogenicity and immunogenicity in the rabbit model.

M Thungapathra1, C Sharma, N Gupta, R K Ghosh, A Mukhopadhyay, H Koley, G B Nair, A Ghosh.   

Abstract

The disease cholera is an important cause of mortality in many developing countries. Though it can be controlled through improved sanitation, this goal is not easily attainable in many countries. Development of an efficacious vaccine offers the best immediate solution. A new oral candidate vaccine has been constructed from a non-toxigenic strain of Vibrio cholerae E1 Tor, Inaba, which is not only devoid of the cholera toxin (CT) virulence cassette but also is completely non-reactogenic in rabbit ileal loop assay. The strain, however, had toxR and tcpA genes. Through a series of manipulations, the ctxB gene of V. cholerae, responsible for the production of the 'B' subunit of the cholera toxin (CTB) was introduced into the cryptic hemolysin locus of the strain. The resulting strain, named vaccine attempt 1.3 (VA1.3), was found to be able to produce copious amounts of CTB. In the RITARD model this strain was found to be non-reactogenic and provided full protection against the challenge doses of both V. cholerae O1, classical and E1 Tor. In the immunized rabbit it invoked significant levels of anti-bacterial and anti-toxin immunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424424     DOI: 10.1016/s0165-2478(99)00076-0

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  6 in total

1.  Cholera in India: an analysis of reports, 1997-2006.

Authors:  S Kanungo; B K Sah; A L Lopez; J S Sung; A M Paisley; D Sur; J D Clemens; G Balakrish Nair
Journal:  Bull World Health Organ       Date:  2010-03       Impact factor: 9.408

Review 2.  Genomic science in understanding cholera outbreaks and evolution of Vibrio cholerae as a human pathogen.

Authors:  William P Robins; John J Mekalanos
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

3.  Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.

Authors:  Chandrika Murugaiah; Nik Zuraina Nik Mohd Noor; Shyamoli Mustafa; Ravichandran Manickam; Lalitha Pattabhiraman
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

4.  Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India.

Authors:  Suman Kanungo; Bandana Sen; Thandavarayan Ramamurthy; Dipika Sur; Byomkesh Manna; Gururaja P Pazhani; Goutam Chowdhury; Puja Jhunjhunwala; Ranjan K Nandy; Hemanta Koley; Mihir Kumar Bhattacharya; Sanjay Gupta; Gaurav Goel; Bindu Dey; Thungapathra M; G Balakrish Nair; Amit Ghosh; Dilip Mahalanabis
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

5.  A single point mutation within the coding sequence of cholera toxin B subunit will increase its expression yield.

Authors:  Bita Bakhshi; Mina Boustanshenas; Masoud Ghorbani
Journal:  Iran Biomed J       Date:  2014-07

6.  A Strategy for the Rapid Development of a Safe Vibrio cholerae Candidate Vaccine Strain.

Authors:  Dmitry S Karpov; Anna V Goncharenko; Evgenii V Usachev; Daria V Vasina; Elizaveta V Divisenko; Yaroslava M Chalenko; Andrei A Pochtovyi; Roman S Ovchinnikov; Valentin V Makarov; Sergei M Yudin; Artem P Tkachuk; Vladimir A Gushchin
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.